Traduction de «Action report » (Anglais → Français) :

Rare disease with manifestations of action tremor associated with relatively mild cerebellar ataxia. Associated pyramidal and extrapyramidal signs and dementia have been reported. Prevalence is unknown. Approximately 40 families have been reported. T

Definition: This category includes certain disorders of behaviour that are not classifiable under other categories. They are characterized by repeated acts that have no clear rational motivation, cannot be controlled, and generally harm the patient's own interests and those of other people. The patient reports that the behaviour is associated with impulses to action. The cause of these disorders is not understood and they are grouped together because of broad descriptive similarities, not because they are known to share any other impo ...[+++]rtant features.

From Vision to Action: Executive Summary: Report of the Health Care System Committee [ From Vision to Action ]

Official Languages: 2002-2003 Perspective: Study of the Action Plan for Official Languages and the Annual Reports of the Office of the Commissioner of Official Languages, Treasury Board and the Department of Canadian Heritage: Interim Report

Progress report, August 24: Action plan of the government of Canada in response to the Royal Society of Canada Expert Panel report Elements of precaution: recommendations for the regulation of food biotechnology in Canada

failure corrective action report

An extremely rare tumour association characterised by dual predisposition to melanoma and neural system tumours (typically astrocytoma). Fewer than 20 affected families have been reported to date. Affected individuals had cutaneous melanoma in associ

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Pyknoachondrogenesis is a lethal skeletal osteochondrodysplasia characterised by severe generalised osteosclerosis. The disease is very rare and only five cases (four males and one female) have been reported in the literature so far. Pyknoachondrogen

General examination and investigation of persons without complaint and reported diagnosis

a.Consolidate various existing tools and reporting mechanisms used to support democracy and promote HR in order to increase coherence and effectiveness of EU action (e.g. HRCS, democracy analyses and APs, reports from election observation, election assistance and follow-up missions, Enlargement Progress Reports, ENP progress reports and APs, civil society engagement roadmaps, assessments of fundamental values for Good Governance and Development Contracts, risk management frameworks for budget support).

With reference to the antimalarial drug mefloquine administered to Canadian Forces bound for Somalia in 1992-93 and the legal framework under which it was available for use and administered: (a) was mefloquine a licensed drug when it was administered to Canadian Forces, if not what was its status, and how was it legally available; (b) were the Canadian Forces participating in the Lariam (mefloquine) Safety Monitoring Study during this period; (c) was the mefloquine administered in accordance with the Lariam Safety Monitoring Study and the Food and Drug Act; (d) who was the “principal investigator” responsible for the Lariam Safety Monitoring Study in the Canadian Forces; (e) who was the Canadian Forces physician responsible to the “prin ...[+++]cipal investigator” of the Lariam Safety Monitoring Study; (f) what was the role of Canadian Forces physician, Dr. Martin Tepper, in the Lariam Safety Monitoring Study; (g) who was responsible for the Lariam Safety Monitoring Study at the Department of Health's Health Protection Branch during this period; (h) what was the role and responsibility of the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drug Act and its regulations in regard to the use of mefloquine by Canadian Forces personnel; (i) when did the Health Protection Branch become aware that mefloquine was being administered to Canadian Forces personnel bound for Somalia; (j) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine to inform the manufacturer of its use; (k) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act to the soldiers who were administered the drug; (l) did the Canadian Forces fulfil their responsibility to the manufacturer under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine and if so how did they do ...

(a) a description of the Commissioner's activities under section 8; (b) the number of notices received pursuant to section 9; (c) the number of notices rejected pursuant to section 12; (d) the number of notices accepted pursuant to section 13; (e) the number of accepted notices that are still under investigation pursuant to subsection 14(1); (f) the number of accepted notices that were reported to ministers pursuant to subsection 14(4); (g) the number of reports to ministers pursuant to section 14 in respect of which action satisfactory to the ...[+++] Commissioner has been taken; (h) the number of reports to ministers pursuant to section 14 in respect of which action satisfactory to the Commissioner has not been taken; (i) an abstract of the substance of all reports to ministers pursuant to section 14 and the responses of ministers pursuant to section 15; and (j) where the Commissioner is of the opinion that the public interest would be best served, the substance of an individual report made to a minister pursuant to section 14 and the response or lack thereof of a minister pursuant to section 15.

(Return tabled) Question No. 116 Hon. Carolyn Bennett: With regard to human trafficking in Canada and the National Action Plan to Combat Human Trafficking: (a) how many individuals were charged with human trafficking, specific offences under sections 279.01, 279.011, 279.02, and 279.03 of the Criminal Code from January 2005 to February 2012 and, in each case, what was the person charged with; (b) how many convictions were there of human trafficking specific offences under sections 279.1, 279.011, 279.02, and 279.03 of the Criminal Co ...[+++]de from January 2005 to February 2012 and, in each case, (i) what was the person convicted of, (ii) what was the sentence, (iii) what other offences (if any) in the Criminal Code was the person charged with, (iv) what other offences, if any, in the Criminal Code was the person convicted of, (v) what was the sentence for each conviction for offences in the Criminal Code; (c) was there consultation done with stakeholders, non-governmental organizations or other interest groups in the development of the government’s National Action Plan to combat Human Trafficking and, if yes, (i) with which stakeholders, non-governmental organizations or other interest groups, (ii) did the stakeholders, non-governmental organization or other interest groups make recommendations to the government, (iii) what were these recommendations, broken down by each stakeholder, non-governmental organization or other interest group, (iv) which recommendations did the government incorporate into the National Action Plan to Combat Human Trafficking, (v) which recommendations did the government not incorporate into the National Action Plan to Combat Human Trafficking and why were they not incorporated; (d) what metrics will the government use to evaluate the effectiveness of the National Action Plan to Combat Human Trafficking and who developed these metrics; (e) what are the metrics to evaluate the effectiveness of the Human Trafficking Taskforce led by Public Safet ...